DIVISION OF METABOLISM, ENDOCRINOLOGY & DIABETES (MEND) CONFERENCE
Elizabeth Weiser Caswell Diabetes Institute Grand Rounds Speaker
Novel developments in incretin-based medications for the treatment of type 2 diabetes and obesity
Michael Nauck, MD
Head of Clinical Research
Diabetes Division of St. Josef-Hospital (Ruhr-University Bochum)
Bochum, North Rhine-Westphalia, Germany
2:00 – 3:00 pm
In-Person at Brehm Tower, 5th Floor, CURE Rm #5050
Professor Michael Nauck, MD has a particular research interest in the role of gastrointestinal peptide hormones (incretins: glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1, GLP-1) in the physiological regulation of metabolism, in the pathophysiology of type 2 diabetes. He has contributed pivotal studies proving a therapeutic potential of GLP-1 in type 2 diabetes. In addition, Professor Nauck has also contributed his expertise to the development of incretin-based glucose-lowering medications such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4.
This seminar is supported by EWCDI in partnership with the MDRC, MNORC, and MCDTR.